HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antiplaque/antigingivitis FDA combination policy endorsed by plaque group.

This article was originally published in The Rose Sheet

Executive Summary

ANTIPLAQUE/ANTIGINGIVITIS COMBINATION POLICY ENDORSED by FDA's Dental Plaque Subcommittee at its meeting May 29 in Gaithersburg, Md. The sub-committee concluded that anticaries and tooth desensitizing agents could be combined appropriately with an approved antiplaque/antigingivitis ingredient or ingredient combination.

You may also be interested in...

W-L Listerine Anticaries Fluoride Rinse Altered Formula Proposed To FDA

Warner-Lambert has changed its proposed fluoride-containing oral anticaries/antiplaque/antigingivitis rinse to a .02% sodium fluoride formula to reflect results from recently conducted market research, W-L says in comments submitted to FDA May 15.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts